Search Back New search Go to resultsDiseaseMain groupSupportive Therapy, ToxicityProtocol groupComplicationsDiseaseExtravasation, Anthracycline (complication)SubgroupICD10T80.-MeSHAnthracyclinesSequenceChemotherapyChemo-substanceChemo-substanceChemo-substanceChemo-substanceNo. Substances RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionDexrazoxaneSupportive substanceBalanced Crystalloid SolutionDexrazoxaneSupportive substanceBalanced Crystalloid SolutionDexrazoxaneSupportive substanceBalanced Crystalloid SolutionDexrazoxaneNo. Substances2Protocol classificationTherapy classificationcurrent standardIntensityStandard doseTherapy indicationTherapy phaseSalvageTherapy intentionsupportiveRisksDiarrheaEmetogenicityFatigueInfectionsPyrexia only studiesPublicationAuthorMouridsen HDiseaseExtravasation nach Anthrazyklin, ECOG 0-2OriginDepartment of Oncology, Copenhagen University Hospital, DenmarkProtocols in Revision 1 protocol foundProtocols under revision.Dexrazoxane 1000 / 500, anthracycline extravasation (PID59 V1.1)
